89. Jahrestagung der Deutschen Gesellschaft für Kardiologie
Donnerstag, 13. April 2023 (Saal 17) 08:00-09:30
Hotline
Late Breaking Clinical Trials I
Vorsitz: W. Döhner (Berlin), P. Lurz (Leipzig)
08:00
(V372)
Effect Of Empagliflozin On Clinical Events in Patients Hospitalized For Acute Heart Failure: From The EMPULSE Trial - Sprecherin
C. E. Angermann (Würzburg)
08:07
(V373)
Effect Of Empagliflozin On Clinical Events in Patients Hospitalized For Acute Heart Failure: From The EMPULSE Trial - Diskutant
R. Pfister (Köln)
08:11
Diskussion
08:15
(V374)
Prolonged Intensified Medical Treatment to Improve Left Ventricular Function in Newly Diagnosed Heart Failure: the HF-OPT Study - Sprecher
C. G. Veltmann (Bremen)
08:22
(V375)
Prolonged Intensified Medical Treatment to Improve Left Ventricular Function in Newly Diagnosed Heart Failure: the HF-OPT Study - Diskutant
A. M. Zeiher (Frankfurt am Main)
08:26
Diskussion
08:30
(V376)
Temporal trends in transcatheter edge-to-edge therapy for primary mitral regurgitation: Results of the worldwide, multicenter PRIME-MR registry - Sprecher
B. Köll (Hamburg)
08:37
(V377)
Temporal trends in transcatheter edge-to-edge therapy for primary mitral regurgitation: Results of the worldwide, multicenter PRIME-MR registry - Diskutant
A. Öner (Rostock)
08:41
Diskussion
08:45
(V378)
Initial therapeutic anticoagulation with rivaroxaban tends to improve the clinical outcomes in COVID-19 (COVID-Prevent) - Sprecher
U. Landmesser (Berlin)
08:52
(V379)
Initial therapeutic anticoagulation with rivaroxaban tends to improve the clinical outcomes in COVID-19 (COVID-Prevent) - Diskutant
A. Goette (Paderborn)
08:56
Diskussion
09:00
(V380)
Differences in Baseline Iron Status and in the Treatment Response to Empagliflozin in Heart Failure Patients with and without Anemia: From the EMPATROPISM-FE Trial - Sprecherin
C. E. Angermann (Würzburg)
09:07
(V381)
Differences in Baseline Iron Status and in the Treatment Response to Empagliflozin in Heart Failure Patients with and without Anemia: From the EMPATROPISM-FE Trial - Diskutant
T. Kempf (Hannover)
09:11
Diskussion
09:15
(V382)
The HighLife TSMVR Feasibility Study – First 30 consecutive Patients, one-year Follow-up completed - Sprecher
L. Schneider (Ulm)
09:22
(V383)
The HighLife TSMVR Feasibility Study – First 30 consecutive Patients, one-year Follow-up completed - Diskutant
J. Hausleiter (München)
09:26
Diskussion
09:30 - 11:00
Pause - Posterdiskussion
